{"id":18070,"date":"2020-05-05T10:28:43","date_gmt":"2020-05-05T03:28:43","guid":{"rendered":"https:\/\/pharmog.com\/wp\/?p=18070"},"modified":"2025-01-08T20:58:24","modified_gmt":"2025-01-08T13:58:24","slug":"brentuximab-adcetris","status":"publish","type":"post","link":"https:\/\/pharmog.com\/wp\/brentuximab-adcetris\/","title":{"rendered":"Brentuximab – Adcetris"},"content":{"rendered":"

<\/span>Th\u00f4ng tin t\u1edd h\u01b0\u1edbng d\u1eabn s\u1eed d\u1ee5ng c\u1ee7a thu\u1ed1c Adcetris<\/span><\/h1>\n

Adcetris (Brentuximab) l\u00e0 thu\u1ed1c ph\u00e1t minh do c\u00f4ng ty Takeda s\u1ea3n xu\u1ea5t, thu\u1ed1c c\u00f3 ch\u1ee9a th\u00e0nh ph\u1ea7n ch\u00ednh l\u00e0 d\u01b0\u1ee3c ch\u1ea5t Brentuximab vedotin. Brentuximab vedotin \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng \u1edf ng\u01b0\u1eddi l\u1edbn \u0111\u1ec3 \u0111i\u1ec1u tr\u1ecb b\u1ec7nh u lympho Hodgkin v\u00e0 u lympho to\u00e0n th\u00e2n t\u1ebf b\u00e0o l\u1edbn tho\u00e1i bi\u1ebfn ho\u1eb7c u lympho \u1edf da t\u1ebf b\u00e0o T. Ngo\u00e0i ra Brentuximab c\u0169ng c\u00f3 th\u1ec3 \u0111\u01b0\u1ee3c s\u1eed d\u1ee5ng k\u1ebft h\u1ee3p v\u1edbi c\u00e1c ph\u01b0\u01a1ng ph\u00e1p \u0111i\u1ec1u tr\u1ecb ung th\u01b0 kh\u00e1c v\u00e0 m\u1ed9t s\u1ed1 b\u1ec7nh kh\u00e1c m\u00e0 kh\u00f4ng \u0111\u01b0\u1ee3c li\u1ec7t k\u00ea trong t\u1edd h\u01b0\u1edbng d\u1eabn s\u1eed d\u1ee5ng n\u00e0y. D\u01b0\u1edbi \u0111\u00e2y l\u00e0 n\u1ed9i dung t\u1edd h\u01b0\u1edbng d\u1eabn s\u1eed d\u1ee5ng c\u1ee7a Thu\u1ed1c Adcetris (Th\u00f4ng tin bao g\u1ed3m li\u1ec1u d\u00f9ng, c\u00e1ch d\u00f9ng, ch\u1ec9 \u0111\u1ecbnh, ch\u1ed1ng ch\u1ec9 \u0111\u1ecbnh, th\u1eadn tr\u1ecdng, d\u01b0\u1ee3c l\u00fd…):<\/em><\/p>

\n
\n

N\u1ed9i dung ch\u00ednh<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n

  • Th\u00f4ng tin t\u1edd h\u01b0\u1edbng d\u1eabn s\u1eed d\u1ee5ng c\u1ee7a thu\u1ed1c Adcetris<\/a>
    • 1. T\u00ean ho\u1ea1t ch\u1ea5t v\u00e0 bi\u1ec7t d\u01b0\u1ee3c:<\/a><\/li>
    • 2. D\u1ea1ng b\u00e0o ch\u1ebf – H\u00e0m l\u01b0\u1ee3ng:<\/a><\/li>
    • 3. Th\u00f4ng tin d\u00e0nh cho ng\u01b0\u1eddi s\u1eed d\u1ee5ng:<\/a>
      • 3.1. Adcetris l\u00e0 thu\u1ed1c g\u00ec?<\/a><\/li>
      • 3.2. C\u00e2u h\u1ecfi th\u01b0\u1eddng g\u1eb7p ph\u1ed5 bi\u1ebfn:<\/a><\/li><\/ul><\/li>
      • 4. Th\u00f4ng tin d\u00e0nh cho nh\u00e2n vi\u00ean y t\u1ebf:<\/a>
        • 4.1. Ch\u1ec9 \u0111\u1ecbnh:<\/a><\/li>
        • 4.2. Li\u1ec1u d\u00f9ng – C\u00e1ch d\u00f9ng:<\/a><\/li>
        • 4.3. Ch\u1ed1ng ch\u1ec9 \u0111\u1ecbnh:<\/a><\/li>
        • 4.4 Th\u1eadn tr\u1ecdng:<\/a><\/li>
        • 4.5 S\u1eed d\u1ee5ng cho ph\u1ee5 n\u1eef c\u00f3 thai v\u00e0 cho con b\u00fa:<\/a><\/li>
        • 4.6 T\u00e1c d\u1ee5ng kh\u00f4ng mong mu\u1ed1n (ADR):<\/a><\/li>
        • 4.7 H\u01b0\u1edbng d\u1eabn c\u00e1ch x\u1eed tr\u00ed ADR:<\/a><\/li>
        • 4.8 T\u01b0\u01a1ng t\u00e1c v\u1edbi c\u00e1c thu\u1ed1c kh\u00e1c:<\/a><\/li>
        • 4.9 Qu\u00e1 li\u1ec1u v\u00e0 x\u1eed tr\u00ed:<\/a><\/li><\/ul><\/li>
        • 5. C\u01a1 ch\u1ebf t\u00e1c d\u1ee5ng c\u1ee7a thu\u1ed1c :<\/a>
          • 5.1. D\u01b0\u1ee3c l\u1ef1c h\u1ecdc:<\/a><\/li>
          • 5.2. D\u01b0\u1ee3c \u0111\u1ed9ng h\u1ecdc:<\/a><\/li>
          • 5.3. Hi\u1ec7u qu\u1ea3 l\u00e2m s\u00e0ng:<\/a><\/li>
          • 5.4. D\u1eef li\u1ec7u ti\u1ec1n l\u00e2m s\u00e0ng:<\/a><\/li><\/ul><\/li>
          • 6. Ph\u1ea7n th\u00f4ng tin k\u00e8m theo c\u1ee7a thu\u1ed1c:<\/a>
            • 6.1. Danh m\u1ee5c t\u00e1 d\u01b0\u1ee3c:<\/a><\/li>
            • 6.2. T\u01b0\u01a1ng k\u1ef5 :<\/a><\/li>
            • 6.3. B\u1ea3o qu\u1ea3n:<\/a><\/li>
            • 6.4. Th\u00f4ng tin kh\u00e1c :<\/a><\/li>
            • 6.5 T\u00e0i li\u1ec7u tham kh\u1ea3o:<\/a><\/li><\/ul><\/li>
            • 7. Ng\u01b0\u1eddi \u0111\u0103ng t\u1ea3i \/T\u00e1c gi\u1ea3:<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n\n

              <\/span>1. T\u00ean ho\u1ea1t ch\u1ea5t v\u00e0 bi\u1ec7t d\u01b0\u1ee3c: <\/strong><\/span><\/h2>\n

              Ho\u1ea1t ch\u1ea5t :<\/em> Brentuximab (Brentuximab vedotin)<\/a><\/strong><\/p>\n

              Ph\u00e2n lo\u1ea1i: <\/em><\/strong>Thu\u00f4\u0301c ch\u00f4\u0301ng ung th\u01b0 > Kh\u00e1ng th\u1ec3 \u0111\u01a1n d\u00f2ng.<\/em><\/p>\n

              Nh\u00f3m<\/em><\/strong> ph\u00e1p l\u00fd: <\/em><\/strong>Thu\u1ed1c k\u00ea \u0111\u01a1n ETC \u2013 (Ethical drugs, prescription drugs, Prescription only medicine)<\/em><\/p>\n

              M\u00e3 ATC<\/em><\/strong> (Anatomical Therapeutic Chemical): L01XC12.<\/p>\n

              Bi\u1ec7t d\u01b0\u1ee3c g\u1ed1c:<\/em><\/strong> Adcetris<\/p>\n

              H\u00e3ng s\u1ea3n xu\u1ea5t <\/em><\/strong>: BSP Pharmaceuticals S.p.A (C\u1edf s\u1edf \u0111\u00f3ng g\u00f3i v\u00e0 xu\u1ea5t x\u01b0\u1edfng : Takeda Austria GmbH. \u0110\/c: St.Peter Strasse 25, 4020 Linz – Austria).<\/p>\n

              H\u00e3ng \u0111\u0103ng k\u00ed<\/em><\/strong>: Takeda Austria GmbH.<\/p>\n